Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
N. Vakil, S. Van Zanten, P. Kahrilas, J. Dent, R. Jones.
The Montreal Definition and Classification of gastroesophageal reflux disease: a global evidence-based Consensus.
Am J Gastroenterol, 101 (2006), pp. 1900-1920
[2.]
J. Ponce, O. Vegazo, B. Beltran, Iberg Study Group, et al.
Prevalence of gastroesophageal reflux disease in Spain and associated factors.
Aliment Pharmacol Ther, 23 (2006), pp. 175-184
[3.]
M.E. Numans, J. Lau, N.J. De Wit, P.A. Bonis.
Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics.
Ann Intern Med, 140 (2004), pp. 518-527
[4.]
M. Rodríguez-Téllez.
Valor diagnóstico de la inhibición ácida potente en la ERGE.
Gastroenterol Pract, 16 (2007), pp. 26-29
[5.]
B. Van Pinxteren, M.E. Numans, P.A. Bonis, J. Lau.
Short-term treatment with proton puma inhibitors, H2 receptor antagonists and prokinetics for gastroesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
Cochrabe Database Syst Rev, (2004),
[6.]
M. Khan, J. Santana, C. Donnellan, C. Preston, P. Moayyedi.
Medical treatments in the short term management of reflux oesophagitis.
Cochrane Database Syst Rev, 18 (2007),
[7.]
R.H. Jones, A.P.S. Hungin, J. Phillipis, J.G. Mills.
Gastroesophageal reflux disease in primary care in Europe: clinical presentation and endoscopio findings.
Eur J Gen Pract, 1 (1995), pp. 149-154
[8.]
M. Marzo, P. Alonso, X. Bonfill, et al.
Clinical practice guideline on the management of gastroesophageal reflux disease (GERD).
Gastroenterol Hepatol, 25 (2002), pp. 85-110
[9.]
I.T. Beck, M.C. Champion, S. Lemire, et al.
The second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease.
Can J Gastroenterol, 11 (1997), pp. 7-20
[10.]
X. Calvet.
Aproximación coste-efectiva del tratamiento de la ERGE.
Gastroenterol Pract, 16 (2007), pp. 14-17
[11.]
S.N. Willich, M. Nocon, M. Kuling, et al.
Cost of disease analisis in patients with gastro-oesophageal reflux disease and Barrett's mucosa.
Aliment Pharmacol Ther, 23 (2006), pp. 371-376
[12.]
J. Zacny, M. Zamakhshary, I. Sketris, S. Veldhuyzen van Zanten.
Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonist or proton puma inhibitors for gastroesophageal reflux disease patients.
Aliment Pharmacol Ther, 21 (2005), pp. 1299-1312
[13.]
B. Bour, J.L. Staub, M. Chousterman, et al.
Long-term treatment of gastroesophageal reflux disease patients with frecuent symptomatic relapse using rabeprazole: on-demand treatment compared with continuous treatment.
Aliment Pharmacol Ther, 21 (2005), pp. 805-812
[14.]
R. Carlsson, J. Dent, R. Watts, et al.
Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with Omeprazole. International GORD Study Group.
Eur J Gatroenterolo Hepatol, 10 (1998), pp. 119-124
[15.]
D.A. Revicki, J.A. Crawley, M.W. Zodet, D.S. Levine, B.O. Joelsson.
Complete resolution of heartburn symptoms and health-related quality of life patients with gastro-oesophageal reflux disease.
Aliment Pharmacol Ther, 13 (1999), pp. 1621-1630
[16.]
D.A. Jonson, M.B. Fennerty.
Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease.
Gastroenterology, 126 (2004), pp. 660-664
[17.]
J.J. Offma.
The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease.
Am J Gastroenterol, 98 (2003), pp. 8-14
[18.]
J.M. Piqué, K.R. Kulich, O. Vegazoc, et al.
Burden of gastroesophageal reflux disease. Evidence from a recent methodological study in Spain.
Gastroenterol Hepatol, 27 (2004), pp. 300-306
[19.]
I. Wiklund.
Review of the quality of life and burden of illness in gastroesophageal reflux disease.
Dig Dis, 22 (2004), pp. 108-114
[20.]
L.R. Lundell, J. Dent, J.R. Bennett, et al.
Endoscopies assessment of oesophagitis: clinical and functional correlatos and further validation of the Los Angeles classification.
Gut, 45 (1999), pp. 172-180
[21.]
I. Wiklund, K.D. Bardhan, S. Müller-Lissner, et al.
Quality of life during acute and intermittent treatmen of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group.
Ital J Gastroenterol Hepatol, 30 (1998), pp. 19-27
[22.]
M. Prassad, A.M. Rentz, D.A. Revicki.
The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review.
Pharmacoeconomics, 21 (2003), pp. 769-790
[23.]
D.A. Johnson, W.C. Orr, J.A. Crawley, et al.
Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial.
Am J Gastroenterol, 100 (2005), pp. 1914-1922
[24.]
D.A. Revicki.
Patient assessment of treatment satisfaction: methods and practical issues.
Gut, 53 (2004), pp. 58-65
[25.]
B.J. Montgomery.
Salvador Minuchin: the «individual in context».
JAMA, 241 (1979), pp. 1314-1319
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
